IPO GMP Update: Amir Chand, Powerica & Sai Parenterals — Day 3 Snapshot
All three IPOs close for subscription on March 27. Here is a quick look at how each is performing in the grey market:
🟢 Amir Chand Jagdish Kumar Exports IPO
- GMP: ₹6
- Estimated Listing Price: ₹218 (2.83% above IPO price of ₹212)
- Grey Market Trend: Upward — strong listing expected
- About: Known for its "Aeroplane" brand basmati rice. Money raised will be used for working capital needs.
🟡 Powerica IPO
- GMP: ₹1
- Estimated Listing Price: ₹396 (0.25% above IPO price of ₹395)
- Grey Market Trend: Declining — weak listing signals
- About: IPO size reduced to ₹1,000 crore from originally planned ₹1,400 crore. Includes fresh issue of ₹700 crore and OFS of ₹300 crore.
🔴 Sai Parenterals IPO
- GMP: ₹0
- Estimated Listing Price: ₹392 (at issue price, no premium)
- Grey Market Trend: Flat — no significant movement expected till listing
- About: Money raised will be used to grow its global medicines business and strengthen its injectable and oral medicines manufacturing capabilities.
Overall Market Mood
Investor sentiment remains cautious due to ongoing market volatility. Amir Chand leads the pack, Powerica shows weak interest, and Sai Parenterals has received a mixed response with only 41% subscription by Day 2.
📚 Educational Note: Grey Market Premium (GMP) is an unofficial indicator of how a stock may list on the stock exchange. A positive GMP means investors expect the stock to list above its issue price, while a zero or negative GMP suggests a flat or weak listing. GMP is not regulated and should not be the sole basis for investment decisions. Always look at the company's fundamentals, financials, and long-term growth potential before applying for any IPO.</sup></sub>
⚠️ SEBI Disclaimer: This content is purely for educational and informational purposes only and should not be considered as investment advice or a recommendation to buy or sell any securities. Grey market activities are unofficial and unregulated. Investing in IPOs and securities markets is subject to market risks. Please read all offer-related documents including the Red Herring Prospectus (RHP) carefully before investing. Readers are advised to consult a SEBI-registered investment advisor before making any financial decisions. Past performance and grey market trends are not indicative of future listing performance or returns.
